MARK HAYGOOD: Open Payments
NPI 1073834370 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$103,698 in 260 payments from 17 companies in 2025. Trend: 2023 $50,751 · 2024 $45,587 · 2025 $103,698
Speaker / faculty: $83,992Travel & lodging: $7,544Consulting: $6,888Food & beverage: $5,275
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 97 | $85,750 |
| ABBVIE INC. | 59 | $15,405 |
| Axsome Therapeutics, Inc. | 18 | $583 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $435 |
| Teva Pharmaceuticals USA, Inc. | 6 | $370 |
| E.R. Squibb & Sons, L.L.C. | 18 | $313 |
| Vanda Pharmaceuticals Inc. | 12 | $169 |
| Otsuka America Pharmaceutical, Inc. | 9 | $163 |
| Supernus Pharmaceuticals, Inc. | 7 | $132 |
| Janssen Pharmaceuticals, Inc | 4 | $103 |
Products named: INGREZZA, VRAYLAR, Auvelity, CAPLYTA, AUSTEDO XR, COBENFY, REXULTI, FANAPT.
Industry payments across AL — which companies pay providers there.
